The first study in a population of muscular dystrophy patients (DMD, BMD, LGMD) receiving myostatin inhibitors was a phase I/II trial with MYO-029 (stamulumab, Wyeth Pharmaceuticals, now Pfizer) [154]. The gene discussed is MSTN; the disease is muscular dystrophy.